Despite Challenges RNAi-based Therapies Have Made Huge Progress, says New Report
News Nov 13, 2009
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analyzing partnering agreements in diagnostics.
“Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities”, which is available at bit.ly/4hSRfd, reports that over the last decade, tremendous advances have been made in the field of RNAinterference (RNAi), a naturally occurring mechanism for gene regulation. Researchers have begun to unravel the underlying mechanisms of gene silencing and along the way a number of new gene silencing agents have been uncovered such as microRNAs.
The 225 page report assesses the commercial potential of RNAi-based therapies in all of the key therapeutic areas: cancer, CNS disorders, viral infectious diseases, ocular diseases, cardiovascular, metabolic and other conditions.
Furthermore it shows that several novel RNAi-based therapeutics are expected to be launched in the next ten years as companies have made significant advances in identifying, characterizing, designing and delivering gene silencing agents to a variety of target tissues.
Whilst RNAi has become a useful tool for understanding the function of specific genes and a means of identifying new targets for small molecule intervention, many scientists have harnessed its power to develop RNAi-based therapeutics, which can treat and in some cases prevent disease and have expanded the repertoire of targets previously deemed 'undruggable'.
In addition, a second generation of RNAi therapeutics, dicer substrate RNA (disRNA), have been discovered that act higher up the RNAi pathway than siRNAs and use endogenous enzymes to process them into siRNAs. Interestingly, this new class of RNA-based therapeutics appear to be more potent and have a longer duration of action than their siRNA counterparts.
However, this field is still in its infancy and the full potential of RNA-based therapeutics has yet to be realized. To date, no RNAi-based therapeutic has been approved, although several products are in clinical development.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
Bird and Turtle Chromosomes Help Identify Dinosaur DNANews
Researchers have used bird and turtle DNA to extrapolate the chromosome structure of their common ancestor that lived around 260 million years ago – 20 million years before the dinosaurs first emerged. They were then able to trace the evolution of avian and non-avian dinosaur DNA through to the present day.
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE